13F Portfolios

Spruce Street Capital LP: RELMADA THERAPEUTICS INC (RLMD): Quarterly 13F Position History

As of Q2 2026, Spruce Street Capital LP reported 6,391,328 shares of RELMADA THERAPEUTICS INC (RLMD), worth $44.2M and representing 8.7% of its 13F equity book. Quarter-over-quarter share count change: + 129,214 (+2.1%) . The position first appeared in Q4 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q2 2026 6,391,328 +129,214 +2.1% $44.2M 8.7% $6.9
Q1 2026 6,262,114 +2,175,933 +53.3% $43.0M 10.3% $6.9
Q4 2025 4,086,181 $19.7M 6.5% $4.8

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.

When did Spruce Street Capital LP first disclose a RLMD position in 13F-HR filings?

Spruce Street Capital LP first reported RELMADA THERAPEUTICS INC (RLMD) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.

What was Spruce Street Capital LP's most recent quarter-over-quarter share-count change in RLMD?

Between Q1 2026 and Q2 2026, Spruce Street Capital LP added 129,214 shares of RLMD (+2.1%), bringing the total reported position to 6,391,328 shares at a market value of $44.2M.

Does the implied price-per-share represent Spruce Street Capital LP's cost basis in RLMD?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.